Abstract

553Background: The advent of the Oncotype DX (ODX) test has widely affected chemotherapeutic treatment decisions in patients with early stage hormone receptor positive breast cancer. Patients with ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Association between estrogen receptor status and Oncotype Dx breast recurrence score.
Noman Ahmed Jang Khan ... Mohamed Farouq Alsharedi
Journal of Clinical Oncology | VOL. 39
Noman Ahmed Jang Khan, et. al.Noman Ahmed Jang Khan ... Mohamed Farouq Alsharedi
20 May 2021
Abstract P3-12-23: Utilization and survival benefit of radiation therapy among hormone receptor positive breast cancer patients with recurrence score from Oncotype DX testing
M-C Hsieh ... Q Yu
Cancer Research | VOL. 79
M-C Hsieh, et. al.M-C Hsieh ... Q Yu
15 Feb 2019
The influence of insulin-like Growth Factor-1-Receptor expression and endocrine treatment on clinical outcome of postmenopausal hormone receptor positive breast cancer patients: A Dutch TEAM substudy analysis
Anita Sajet ... Caroline Seynaeve
Molecular Oncology | VOL. 10
Anita Sajet, et. al.Anita Sajet ... Caroline Seynaeve
31 Oct 2015
Abstract P1-06-05: Clinical practice and mortality in patients with oncotype DX intermediate score: What do we know about the gray zone?
F Olopade ... Af Ibraheem
Cancer Research | VOL. 78
F Olopade, et. al.F Olopade ... Af Ibraheem
14 Feb 2018
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes
Cristina Astrid Tentori ... Fabio Ciceri
Journal of Clinical Oncology | VOL. -
Cristina Astrid Tentori, et. al.Cristina Astrid Tentori ... Fabio Ciceri
09 May 2024
Addressing Disability in Cancer Survivors
Rachelle Brick ... Emily S Tonorezos
Journal of Clinical Oncology | VOL. -
Rachelle Brick, et. al.Rachelle Brick ... Emily S Tonorezos
09 May 2024
First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study
Susanna Hegewisch-Becker ... Niall C Tebbutt
Journal of Clinical Oncology | VOL. -
Susanna Hegewisch-Becker, et. al.Susanna Hegewisch-Becker ... Niall C Tebbutt
09 May 2024
A pivotal phase 2 single-arm study of glecirasib (JAB-21822) in patients with NSCLC harboring KRAS G12C mutation.
Yuankai Shi ... Zhengbo Song
Journal of Clinical Oncology | VOL. 42
Yuankai Shi, et. al.Yuankai Shi ... Zhengbo Song
30 Apr 2024
View more papers